Roswell Park's Phase II CPX-351 trial in younger secondary AML patients marked completed
A 21-patient Phase II study testing CPX-351 in secondary AML patients under 60, sponsored by Roswell Park with Jazz Pharmaceuticals as collaborator, has reached completed status.
This week's update covers one trial involving CPX-351 (liposome-encapsulated daunorubicin-cytarabine, also known as Vyxeos).
- The Phase II trial, testing CPX-351 in patients with secondary acute myeloid leukemia younger than 60 years old, is led by Roswell Park Cancer Institute with Jazz Pharmaceuticals as a collaborator1. The study's enrollment reached 21 participants (actual)1, and its overall status is now listed as completed, with primary completion recorded as 2025-05-27 and study completion as 2026-04-161. The primary objective was to determine the complete response rate, including morphologic complete remission and morphologic complete remission with incomplete blood count recovery, as defined by International Working Group Criteria1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.